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Abstract 
 
Understanding the targeted cellular uptake of nanomaterials is an essential step to engineer and 
program functional and effective biomedical devices. In this respect, here we describe the targeting 
and ultra-fast uptake of zeolite nanocrystals functionalized with Cetuximab antibodies (Ctxb) by cells 
overexpressing the epidermal growth factor receptor. Biochemical assays showed that the cellular 
uptake of the bioconjugate over the targeted cancer cells already begun 15 minutes after incubation, 
at a rate around 10-fold faster than that observed in the negative control cells. These findings further 
show the role of Ctxb exposed at the surfaces of the zeolite nanocrystals in mediating the targeted 
and rapid cellular uptake. By using temperature and pharmacological inhibitors as modulators of the 
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internalization pathways, our results univocally suggest a dissipative uptake mechanism of these 
nanomaterials, which seems to occur using different internalization pathways, according to the 
targeting properties of these nanocrystals. Owing to the ultra-fast uptake process, harmless for the 
cell viability, these results further pave the way for the design of novel theranostic tools based on 
nanozeolites. 
 
1. Introduction 
Strong hope is nowadays devoted on nanostructured materials as functional carriers for therapy and 
diagnostic applications.[1] Many of the proposed nanotechnological approaches can in principle bring 
crucial solutions in medicine, and preliminary demonstrations in preclinical or clinical trials were 
reported from several laboratories throughout the world.[2] Among the different applications, 
nanomaterials are under thorough investigation for cancer theranostics[3] due to their wide chemical 
versatility to impart multifunctionality[4] and their possibility to accumulate at the tumor district by 
enhanced permeation and retention effect[5] (EPR). However, an important drawback limiting their 
clinical exploitation entails the inadequate in-vivo accumulation at the targeted site and the 
consequent intracellular localization due to physiological clearance mechanisms such as the 
mononuclear phagocyte system (MPS) uptake.[6] It is therefore of paramount importance to reduce 
the nanomaterial extracellular concentrations. Depending on their structural and morphological 
properties (i.e. chemical composition, shape, size and charges), several classes of nanomaterials have 
been found to cross cell membranes through different and sometimes controversial internalization 
mechanisms, such as endocytosis or membrane penetration.[7] Understanding the internalization 
mechanism of a given nanomaterial is thus an essential step to engineer and program functional 
nanomaterials for hierarchical targeting and drug-delivery applications.[8] 
Current design of nanomaterial for cancer theranostics rely on the use of anchored ligands[2d,9] (i.e. 
folic acid[10] or hyaluronic acid[11]) to impart targeting properties and receptor mediated endocytosis 
(RME).[12] Antibody bioconjugation is an even more convenient strategy for nanomaterial 
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functionalization because, compared to other ligand-based approaches, yielded derivatives retaining 
their biological properties even in serum supplemented medium, being thus resistant to the biological 
modulation by the protein-corona.[13] Monoclonal antibody Cetuximab[14] (Ctxb) is one of the best 
candidates to target the epidermal growth factor receptor (EGFR), a marker overexpressed in several 
kind of cancers.[15] In this respect, Ctxb nano-bioconjugates retained such epitope targeting,[15c,16] thus 
displaying fast in-vitro internalization (already 30 minutes after incubation),[16e,16j,16k] enhanced 
uptake compared to pegylated materials (about 15-fold 2 hours after incubation), and resilient in-vivo 
accumulation at the tumor site.[15c,16a,16c,16h,17] 
Due to their peculiar physicochemical properties and payload delivery capacity, silica-based 
nanomaterials are largely explored nowadays for biomedical applications,[4b,18] with some examples 
of nanoparticle-antibody hybrids showing enhanced binding to cancer cells and tumor 
accumulation.[15c,19] In this respect, zeolite nanocrystals emerged as potent biomedical tools for 
imaging applications and as a platform for cell growth and interactions,[20] since they show defined 
shape and size distributions, and are made of an inorganic framework that allows for both 
encapsulation of luminescent probes and exohedral surface modification. In particular, organic 
functionalized zeolites were efficiently internalized by HeLa cells within 2 and 24 hours, with 
differences in the intracellular accumulation depending on the surface functionalities (carboxyl, 
amino, poly-ethyleneglycol or poly-allylamine moieties).[21] In a consecutive study, the group of De 
Cola further described that zeolite nanocrystals, coated with a biodegradable poly-L-lysine, could be 
internalized already one hour after incubation suggesting a fast intracellular payload delivery.[20f] 
Nonetheless, this material lacks of specific binding moieties or targeted cellular accumulation 
properties.  
In this work, we report on the targeting action and fast cancer cell uptake of fluorescent zeolite 
nanocrystals functionalized with Ctxb antibodies. We observed selective binding of the nano-
bioconjugate to EGFR+ cells, model of epidermoid carcinoma cells, followed by a rapid uptake 
occurring already 15 minutes after addition of the nanomaterial. Temperature- and 
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pharmacologically-modulated internalization studies suggest a dissipative accumulation mechanism 
involving different internalization pathways. 
 
2. Results and discussion 
By exploiting previously established protocols,[21,22] L-zeolite nanocrystals were prepared, 
endohedrally equipped with the red-emitter oxazine-1 fluorophore, and exohedrally functionalized 
with amino-PEG silane (molecular weight about 5,000 gmoL-1), yielding luminescent Zeo-NH2. As 
revealed by porosimetry, TEM and DLS measurements (see section S1), these protocol generates 
porous nanocrystals of around 50-60 nm retaining the red emissive properties of the cavity-confined 
fluorophore (Figures S1d-e). As expected, upon pegylation, the hydrodynamic diameter of the 
resulting Zeo-NH2 nanoparticles increases to ca. 86 nm (Table 1 entries 1 and 2, and Figures S1f-g). 
Ctxb antibody was covalently linked to the nanomaterial by adapting a previously developed 
carbodiimide-mediated amidation protocol[16a,23] to yield the targeting nanozeolite derivative, Zeo-
NHCO-Ctxb (Scheme 1, path a). Since it is known that proteins can irreversibly adsorb onto a large 
variety of nanostructured materials,[24] we verified the occurrence of aspecific Ctxb immobilization 
onto Zeo-NH2 also in the absence of the coupling agent (Zeo-NH2/Ctxb, Scheme 1 path b). X-ray 
photoelectron spectroscopy (XPS, see section S2) of Zeo-NH2 material showed the expected 
elemental composition (O, Si, C, Al, N) fingerprinting the presence of the ethylene glycol C atoms 
(292-298 eV, Figure 1a) and of the terminal amino groups (less than 1 at% of N atoms, Figure 1b). 
XPS spectra of both Zeo-NHCO-Ctxb and Zeo-NH2/Ctxb clearly display the contemporaneous 
presence of C-centered peaks fingerprinting both the ethylene glycol and the polypeptidic molecular 
fragments (Figure 1a) along with an enhanced content of N atoms (around 11 at%), both supporting 
the occurrence of the bioconjugation. By defining the “organic-to-inorganic proportion” as the ratio 
between the sum of C1s and N1s at% divided by the sum of Si2p and Al2p at%, we obtained values 
of 0.4 for Zeo-NH2 and of about 4.0 for Zeo-NHCO-Ctxb and Zeo-NH2/Ctxb, revealing a comparable 
loading of Ctxb for the covalent vs non-covalent anchoring of the antibody. Similar findings also 
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resulted from a “bulk” characterization such as thermogravimetric analysis (TGA), performed both 
under N2 (to assess pyrolysis, Figure 1c) and air atmosphere (Figure S3). As expected, the TGA traces 
for the sample containing Zeo-NH2 confirmed the low amount of the organic content and 
oligoethylene-derived pyrolysis,[25] whereas the characteristic weight loss profile (minimum at 
around 320 °C, Figure 1c) underpinning the presence of Ctxb is clearly visible for both Zeo-NHCO-
Ctxb and Zeo-NH2/Ctxb.[16a,23] The Ctxb loading resulted to be 2.0 and 1.7 nmolmg-1 for hybrids Zeo-
NHCO-Ctxb and Zeo-NH2/Ctxb, respectively (see S3).  
To further unravel the necessity and efficacy of the covalent bioconjugation protocol, we analyzed 
the zeolite derivatives through fluorescence revelation after gel electrophoresis separation. Indeed, 
the cavity-confinement of the oxazine-1 fluorophore allows for the intrinsic detection of the zeolite 
framework (λexc = 633 nm), whereas the amino groups of both PEG-NH2 moiety and antibody can be 
easily labelled with a specific green fluorescent dye (Cy2® NHS, λexc = 488 nm). This consents the 
discrimination between the covalent- and loosely-bound Ctxb moieties (see Figure 1 and S4). As 
references, lanes 1, 2 and 3 were loaded with three different amounts of Ctxb (approximately 66, 44 
and 22 fmol, respectively), whereas the lanes 4, 5 and 6 were loaded with the zeolite materials (Zeo-
NH2, Zeo-NHCO-Ctxb and Zeo-NH2/Ctxb from 1.0 mgmL-1 solutions, approximately 0, 40 and 34 
fmol of Ctxb, respectively). After gel electrophoresis, the Ctxb bands located at about two-thirds of 
the migration path, and show dose-dependent fluorescence intensities in the reference lanes 1,2 and 
3. On the contrary, lane 4, tracing Zeo-NH2, displayed no green fluorescence due to the absence of 
Ctxb and the low amount of PEG-NH2 moiety. Lanes 5 and 6, respectively tracing Zeo-NHCO-Ctxb 
and Zeo-NH2/Ctxb derivatives, showed co-localized green and red fluorescence at the deposition 
spots and a great release of free Ctxb for the hybrid prepared in the absence of the coupling agent 
(Zeo-NH2/Ctxb). This supports the idea for which non-negligible supramolecular interactions might 
occur between Ctxb and the nanomaterial, favoring a non-covalent association, as previously 
observed with CNT materials.[23a,26] Nonetheless, the use of the carbodiimide-mediated ligation 
protocol irreversibly strengthened the association between the two counterparts, as previously 
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reported for AuNPs-Ctxb and CNT-Ctxb analogues.[16a,23] It is known that serum proteins can adsorb 
onto the nanoparticle surface,[24,27] with some literature examples reporting dramatic diameter 
increases after protein corona formation (i.e., 2- to 10-fold for citrate-capped AuNPs of 15, 40 and 
80 nm).[28] Given these premises, we determined the hydrodynamic diameters of Zeo-NH2 and Zeo-
NHCO-Ctxb, in serum supplemented medium (DMEM + 10% fetal bovine serum), which resulted to 
be 110 nm (PDI 0.113, Table 1 entry 2) and 117 nm (PDI 0.300, Table 1 entry 3), respectively. By 
further monitoring the dispersions as a function of the incubation time (0.5, 7, and 24h), one can 
clearly notice a minor increase of the size distributions up to 24h (109.5 ± 28.7 nm, 108.6 ± 28.6 nm, 
and 113.7 ± 28.3 nm for Zeo-NH2, and 136.6 ± 67.2 nm, 143 ± 67.4 nm, and 152.1 ± 66.6 nm for 
Zeo-NHCO-Ctxb, after 0.5h, 7h and 24h), thus suggesting reduced protein adsorption and limited 
particle aggregation, in line with what found for other PEGylated nanomaterials.[29] Notably, no 
signature of free Ctxb was observed in the samples containing Zeo-NHCO-Ctxb (see S5), which 
suggests the lack of a Ctxb “soft corona” in line with the gel-electrophoresis findings. Regarding the 
particle electrophoresis, Ctxb, Zeo-NH2, and Zeo-NHCO-Ctxb displayed negative ζ potential values 
of around -8.9 mV, -22.7 mV, and -35.7 mV, respectively, proving the progressive increase of 
positive charges due to the presence of amino-PEG and Ctxb moieties (Table 1 entries 2,3 and 4).  
 Aiming at assessing a possible effect of the zeolite nanocrystals on the cell viability, we have 
incubated both EGFR+ cells and EGFR- cells with Zeo-NHCO-Ctxb and Zeo-NH2 at equivalent 
nanocrystal concentrations (0 – 0.16 mgmL-1, Figure 2). It is known that nanoparticles can interfere 
with the common reagents used for assessing cell viability due to the spectral overlap or fluorescence 
quenching, amongst others.[30] Since our luminescent nanocrystals may interfere with the reagents of 
cytotoxicity assays based on either red-absorbing chromophores (i.e., resazurin or trypan blue), or 
fluorescent probes (i.e., Rhodamine derivatives or Ethidium bromide/acridine orange), we have 
adapted the MTS assay protocols (see section S6) to assess the cell viability. As displayed in the cell 
viability plot (Figure 2), one can exclude a dramatic effect of all nanomaterials on the cell viability 
of both EGFR+ and EGFR- cell lines after 24h of incubation.  
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To verify whether Zeo-NHCO-Ctxb retained the key property like other Ctxb-exposing nanomaterials 
of binding preferentially EGFR+ cells over those EGFR-, we selected human epidermoid carcinoma 
A431 cells, overexpressing the epitope EGFR (EGFR+), and human endothelial cells (EAhy926 
cells), which do not express this receptor (about 200-fold less, see Table S7).[16a,23] The selection of 
the EAhy926 cells as the negative control is dictated by the necessity of evaluating the aspecific 
binding and internalization by the components of the endothelial barrier, which can lead to an in-
vivo extravasation of the nanomaterial, further reducing the bioavailability at the tumor site.[16a,23] 
Confocal microscopy analysis of EGFR+ cells incubated with Zeo-NHCO-Ctxb allowed for the cell 
identification through the far-red channel, clearly displaying a positive response between the targeted 
cells and the fluorescent nanomaterial (see Section S8). By repeating the test with the negative 
control, no cell identification was possible through the far-red channel, which showed Zeo-NHCO-
Ctxb particles randomly fluctuating in the medium and thus lacking any kind of targeting action 
toward EGFR- cells (see Section S9). This observation is supported by the results from cell-based 
ELISA experiments onto adherent cells, which reported higher binding events of Zeo-NHCO-Ctxb 
onto the EGFR+ cells compared to the negative controls (Figure S10).[16a,23a]” We next assessed 
whether Zeo-NHCO-Ctxb could detect the presence of EGFR+ cells in a mixed suspension with the 
negative control. To this aim, we labelled EGFR- cells with a green fluorescent dye (Vybrant® DIO, 
λexc = 488 nm), mixed with unlabeled EGFR+ cells (about 1:1 ratio), and added Zeo-NHCO-Ctxb. 
The resulting mixture was incubated for 2.5 min, and then analyzed through confocal microscopy 
(Figure 3). The suspended EGFR+ and EGFR- cells possess similar shape and size, and cannot be 
discriminated by the differential interference contrast (DIC) channel (Figure 3, row a). Excitation at 
488 nm clearly revealed the labelled EGFR- cells (Figure 3, row b), while excitation at 633 
highlighted the EGFR+ ones (Figure 3, row c). The overlay of the three channels unambiguously 
allowed the color-based identification of the cells types in the suspension, being the EGFR+ cells 
stained in red due to the targeting and luminescent zeolites, and the EGFR- cells colored only in green 
due to the pre-staining procedure (Figure 3, row d). These binding studies highlight that, regardless 
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of the use of adherent or suspended cells (for ELISA and confocal microscopy, respectively) or the 
incubation media (serum-free for ELISA, serum-containing medium for confocal microscopy), Zeo-
NHCO-Ctxb always binds rapidly and specifically to the EGFR+ cells. 
In order to unravel the internalization process and to study the uptake mechanisms (i.e., through 
physical membrane permeation or endocytosis),[7] we prepared adherent cells and performed both 
flow cytometry and confocal microscopy investigations.[31] Regarding the flow cytometry analysis, 
since the nanomaterial uptake depend on several factors, we have determined the extent of the uptake 
by fixing two levels for 3 variables, such as the “cell type” (EGFR+ cells or EGFR- cells), the “cell 
medium” (10% serum or serum-free medium), the “nanomaterial” (Zeo-NHCO-Ctxb or Zeo-NH2 
nanoparticles) and 6 levels for the variable “incubation time” (15, 45, 95, 150, 360 or 1440 min). The 
resulting 48 experimental combinations were performed in independent sets of experiments, to gather 
a dataset amenable for both graphical representation of the time-dependent uptake profiles (Figure 
S11), as well as statistical evaluation. The degree of the uptake is reported as absolute values (% of 
positive cells, Figures 4a-c) and normalized values ([(% of positive cells)/ highest % of positive cells) 
x 100]), the latter better highlighting the internalization speed (Figures 4b-e). The uptake profiles 
qualitatively indicate that, after short incubation times (range 15 – 150 min), Zeo-NHCO-Ctxb always 
determine enhanced staining compared to Zeo-NH2, with the latter requiring prolonged incubation 
time to reach the maximal uptake (360 or 1440 min). By defining IT50 as the incubation time necessary 
to reach half of the highest staining proportion, it is possible to estimate the IT50 values for Zeo-
NHCO-Ctxb that reveal to be 15 – 45 and 95 – 150 min for the EGFR+ cells and EGFR- cells, 
respectively. On the contrary, non-targeting Zeo-NH2 displayed IT50 values of 150 – 360 and 360 – 
1440 min for the EGFR+ cells and EGFR- cells, respectively. The statistical evaluation of the 
normalized values by one-way analysis of variance (ANOVA) unambiguously suggests a fast 
internalization of the Ctxb-bioconjugated particles by the EGFR+ cells (Figures 4c-f).  
Two-way ANOVA assessments can elucidate different aspects of the uptake regulation, such as the 
influence of factors accounting for one specific variable (i.e., “incubation time”), or two variables 
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(i.e., “nanomaterial biological interface”, which combines “nanomaterial” and “cell medium”) and 
whether these factors are linked or not. We thus performed different two-way ANOVA studies. In 
particular, building the two-way ANOVA with the “incubation time” factor (Figures 5a-b) reveals a 
shallower uptake profile for the EGFR+ cells compared to the EGFR- cells. This further confirms 
that already after short incubation times the nanoparticles uptake is close to its maximal value. On 
the other hands, the time-independent profiles show a higher Zeo-NHCO-Ctxb uptake than that of 
Zeo-NH2 (about 2 fold, Figures 5c-d) and a strong link between “incubation time” and “nanocrystal 
biological interface” (interaction with p < 0.00001 for the EGFR+ cells). Statistically significant 
differences and connections between the factors also emerge by using the variables “cell type” (Figure 
5e, p < 0.0001) and “nanomaterial” (Figure 5f, p < 0.00001). This clearly indicates that the EGFR+ 
cells internalize more rapidly the zeolite nanocrystals than the EGFR- cells (57±4% vs 44±5%), and 
that the Zeo-NHCO-Ctxb particles are faster internalized than its precursor Zeo-NH2 (66±4% vs 
34±4%).  
Taken together, all the ANOVA results indicate a faster uptake of the Ctxb nano bioconjugate by the 
EGFR+ cells, and that: i) incubation time; ii) cell type; iii) the presence of Ctxb are the key factors 
triggering the uptake of the zeolite nanocrystals. Both graphical profile and statistical analysis did not 
reveal any dramatic effect of the variable “cell medium” in determining statistically significant 
changes in the uptake, thus suggesting a limited role of the serum in affecting the cell uptake of these 
zeolite-based nanomaterials.  
To discriminate between the effective extracellular, membrane-bound or intracellular nanocrystals 
localization, we fluorescently stained the nucleus by Hoechst reagent (λexc = 400 nm), cytoskeleton 
components (F-actin) using AlexaFluor488-Phalloidin® (λexc = 488 nm) and used cell segmentation 
by confocal microscopy (Figure S12a). We incubated both EGFR+ and EGFR- cells with either Zeo-
NHCO-Ctxb or Zeo-NH2 in serum containing medium for 15 or 150 minutes, since these incubation 
conditions were the lower limit to observe nanocrystal uptake and discriminate between the two cell 
lines. Experiments performed at 37 °C (Figure 6 and S12) showed some Zeo-NHCO-Ctxb particles 
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surrounded by membrane invaginations or completely internalized already 15 minutes after 
incubation (Figure 6a). On the contrary, internalization of Zeo-NH2 zeolites was not detected after 
such short incubation times (Figure 6e). After 150 minutes of incubation, several Zeo-NHCO-Ctxb 
particles were observed intracellularly (Figure 6b), while only few clusters of Zeo-NH2 co-localized 
with membrane invaginations were detected (Figure 6f). The presence of Zeo-NHCO-Ctxb or Zeo-
NH2 nanocrystals inside the targeted cells is supported also by TEM imaging (see Figure 7 and S13). 
Reference experiments performed at 4 °C displayed the blockage of the nanomaterial uptake, 
enhanced sedimentation and agglomeration of the nanoparticles. This was more obvious after 
prolonged incubation times (150 minutes, Figure 6c-d-g-h, and S14). The addition of Zeo-NHCO-
Ctxb or Zeo-NH2 to the EGFR- cells induced very few occurrences of membrane invagination and a 
reduced uptake over short incubation times, especially using Zeo-NH2 (see S15).  
To get a deeper insight on the intracellular localization of Zeo-NHCO-Ctxb after very short 
incubation times, we imaged the EGFR+ cells 15, 45 and 95 min after incubation by confocal 
microscopy (Figure 8). The optical sectioning of the corresponding images confirms that after 15 
minutes of incubation some particles seem already undergoing internalization (Figure 8a and S16). 
At 45 minutes, it is already possible to discern the intracellular zeolites in endosomal-like structures, 
as revealed by co-localization with the actin filaments (Figure 8b and S17), eventually leading to a 
further diffusion toward the nucleus at t = 95 minutes (Figure 8c and S18). Again, the nanomaterial 
localization in cells incubated at 4 °C was essentially unchanged under the different incubation times, 
with the Ctxb-functionalized zeolitic nanoclusters predominantly situated at the periphery of the 
plasma membrane (Figure 8d-e-f and S19-21).  
Accounting for the low impact of serum in affecting both the binding properties and the nanocrystal 
uptake, and of the similar colloidal properties of Zeo-NHCO-Ctxb and Zeo-NH2 nanocrystals, these 
results indicate that the Ctxb moiety acts as a specific cell-recognition platform, thus driving the 
selective cellular uptake. Since the temperature-dependent outcomes of the internalization studies 
suggest a dissipative process for the uptake of these nanocrystals, we treated the EGFR+ cells with a 
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panel of pharmacological inhibitors[7f,32] prior to the incubation with Zeo-NHCO-Ctxb or Zeo-NH2. 
We selected hydroxy-dynasore (to block the GTPase activity of dynamin and thus dynamin-
dependent endocytosis, conc. ≈ 60 µM),[33] chlorpromazine (to block the clathrin-dependent 
endocytosis, conc. ≈ 60 µM),[34] genistein (a tyrosine kinase inhibitor that blocks caveolae-dependent 
endocytosis, conc. ≈ 150 µM),[34-35] 5-(N-ethyl-N-isopropyl)-amiloride (a macropinocytosis inhibitor, 
conc. ≈ 30 µM),[36] and nocodazole (a microtubule-depolymerizing agent, conc. ≈ 40 µM).[37] Thanks 
to the steep uptake profiles, we have exposed the cells to the pharmacological inhibitors for relatively 
short times (60 min pre-incubation, 150 min with zeolite nanocrystals) to avoid the cytotoxic effects 
derived from the use of these inhibitors upon prolonged incubation times.[32b,32c] 
The resulting uptake profiles suggest that the internalization of Zeo-NHCO-Ctxb is affected by 
chlorpromazine, amiloride and genistein, whereas the Zeo-NH2 uptake is reduced by dynasore (Figure 
S22). EGFR internalization is known to proceed through different endocytotic pathways (clathrin- 
caveolae-, and dynamin-dependent) depending on cell type and ligand stimulation,[38] while the 
detailed mechanism and physiological relevance of Ctxb internalization remains elusive. For 
instance, literature data about the internalization of Ctxb-Au nanoconjugates suggest that the cell 
type, EGFR+ expression levels, and Ctxb/Au ratio play an important role in dictating the 
internalization mechanism that can occur following different pathways, spanning from dynamin 
dependent and independent routes to caveolar and pinocytotic uptake.[16j,k] Considering this 
background and our experimental findings, it is likely that multiple effectors affect the uptake of Zeo-
NHCO-Ctxb (clathrin- and caveolae-mediated endocytosis, macropinocytosis), which seems to 
follow another pathway than that of Zeo-NH2 under these experimental conditions. 
 
3. Conclusions 
In conclusion, in this work we were able to control the degree of zeolite nanocrystals interaction with 
selected cells through antibody conjugation, and determine differences in the internalization times 
between cancer- and reference- cell lines. The bioconjugated nanomaterial rapidly binds to EGFR+ 
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cells, allowing for their selective detection by confocal microscopy in a mixed population with a 
reference cell line. Interestingly, a different cellular uptake of the Ctxb-functionalized zeolite 
nanocrystals over the selected cell lines was observed already 15 minutes after incubation with the 
EGFR+ cells (almost ten-times faster compared to the use of non-targeting zeolite nanocrystals 
lacking of the targeting antibody). Furthermore, preliminary cytotoxicity investigations excluded 
significant reduction of the cell viability under the chosen experimental conditions. Along with some 
recent literature results,[2d,39] these findings further suggest that the nanomaterial bioconjugation with 
antibodies represents a valuable strategy for the fast intracellular accumulation of nanoparticles, 
consequently limiting physiological clearance processes that are currently hindering the marketing 
potential of several nanomaterials. Considering the wide pool of antibodies approved by the FDA in 
the US and/or Europe and those under clinical developments, the example reported in this article 
represents only the initial step of an increasing effort aimed at the design of versatile theranostic 
systems based on porous nanozeolites as functional hosts. 
 
Supporting Information Detailed experimental part, nanocrystals physicochemical characterization, 
full XPS and TGA results, gel electrophoresis, TEM and confocal microscopy images of both binding 
and internalization experiments. 
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FIGURES 
 
Scheme 1. Synthetic strategies for immobilizing Ctxb onto zeolite nanocrystals through carbodiimide-
mediated (a) or physisorption-based (b) routes. EDC is N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride, NHSS is N-hydroxysulfosuccinimide, and MES is 2-(N-
morpholino)ethanesulfonic acid buffer. 
 
 
Table 1. Summarization of the physicochemical properties of the zeolite nanomaterials. 
Entry Sample DLS (peak, 
PDI*a) 
ζ potential 
[mV]*b 
1 Zeo 56 nm, 
0.319b) 
-24.24 
2 Zeo-NH2 86 nm, 
0.252b); 110 
nm, 0.113c) 
-22.65 
3 Zeo-NHCO-
Ctxb 
117 nm, 
0.300c) 
-35.73 
4 Ctxb 17 nm, 0.178 
b)
 
-8.89 
a): PDI = polydispersity index; b): values obtained from water dispersions; c): values obtained from 
dispersions in serum supplemented biological medium. 
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Figure 1. XPS high-resolution spectra for the C1s (a) and N1s (b) regions and TGA profiles under 
N2 flow at 90 mL min-1 (c) for Ctxb alone, Zeo-NH2, Zeo-NHCO-Ctxb and Zeo-NH2/Ctxb. Two-
channel (λ1exc = 488 nm and λ1em = 500 nm; λ2exc = 633 nm and λ2em = 670 nm) fluorescence images 
of the gel lanes (1-6) after electrophoresis (d-h). Ctxb was loaded on lanes 1, 2 and 3, while Zeo-NH2, 
Zeo-NHCO-Ctxb and Zeo-NH2/Ctxb respectively on lanes 4, 5 and 6. Overlaid fluorescence signals 
located in the deposition area (d) and Ctxb moiety migration band (e). Individual fluorescence at the 
deposition area (lanes 4,5,6) as revealed in the red channel (f), green channel (g), and overlaid channel 
intensities (h). Full gel revelation is reported in S4. 
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Figure 2. Cell viability assessment by MTS assay after 24h incubation with Ctxb (a), Zeo-NHCO-Ctxb 
(b), and Zeo-NH2 (c). Results are expressed as mean ± s.d. (n=4). 
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Figure 3. Confocal microscopy images of different fields (I-IV) of a suspension of EGFR+ cells and 
green fluorescently labelled EGFR- cells after incubation (3 minutes) with Zeo-NHCO-Ctxb 0.4 
mgmL-1. Individual channel intensity (DIC (a), at λexc = 488 nm (b), and λexc = 633 nm (c)) along with 
the overlaid images (d). Image scale bars are 50 µm.  
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Figure 4. Results of the time-dependent nanocrystal uptake evaluation by flow cytometry. Absolute 
proportion of fluorescently stained cells over total cell population (+%, a, d) and normalized values 
((+/max+)%, b, e), along with one-way ANOVA of the resulting dataset (c, f) on the EGFR+ cell (a, 
b, c) or EGFR- cell (d, e, f) population. The red-dashed traces result from experiments performed 
with Zeo-NHCO-Ctxb, while the blue-dotted ones are linked to the use of Zeo-NH2. In both instances, 
the results originating from the incubation in the presence of 10% serum are labelled in each graph. 
* = p < 0.05, ** = p < 0.01. Data are reported as mean ± s.e.m. (n=3 independent sets of experiments).  
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Figure 5. Results of the time-dependent zeolite nanocrystal uptake, as assessed by flow cytometry. 
2-way ANOVA after grouping by the factors “incubation time” (a, b) or “nanocrystal biological 
interface” (c, d) on the individual dataset of EGFR+ cells (a, c) or EGFR- cells (b, d). 2-way ANOVA 
of the whole EGFR+ and EGFR- cells dataset after grouping by the factors “cell type” (e), 
or ”nanomaterial” (f) against all the other respective incubation parameters. * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001, ***** = p < 0.00001. Data are reported as mean ± s.e.m. 
(n=3 independent sets of experiments). 
 
Figure 6. Optical sectioning reporting the fluorescence intensities from nuclei (λexc 400 nm, cyan), 
actin filaments (λexc 488 nm, green) and zeolite nanocrystals (λexc 561 nm, red). Representative images 
of adherent EGFR+ cells after addition of Zeo-NHCO-Ctxb (a, b, c, d) or Zeo-NH2 (e, f, g, h) at 37 °C 
(a, b, e, f) or 4 °C (c, d, g, h), 15 minutes (a, c, e, g) or 150 minutes (b, d, f, h) after incubation. The 
composed images show three parts: the bottom image is the X-Z projection, the right image is the Y-
Z projection and the main image is the X-Y projection, all relative to the white lines identifying the 
XYZ positioning along the 3D z-stack. 
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Figure 7. TEM images of EGFR+ cells incubated for 150 minutes with Zeo-NHCO-Ctxb (a) or Zeo-
NH2 (b). Red arrows point toward some of the clusters that, according to their morphology and 
imaging contrast, are compatible with zeolite nanocrystals (See Figure S13 for additional images). 
 
 
 
Figure 8. Optical sectioning reporting the fluorescence intensities from nuclei (λexc = 400 nm, cyan), 
actin filaments (λexc = 488 nm, green) and zeolite nanocrystals (λexc = 561 nm, red color). 
Representative images of adherent EGFR+ cells upon addition of Zeo-NHCO-Ctxb at 37 °C and after 
different incubation times (a = 15 minutes, b = 45 minutes, and c = 95 minutes), or after incubation 
at 4 °C (d = 15 minutes, e = 45 minutes, and f = 95 minutes). The composed images show three parts: 
the bottom image is the X-Z projection, the right image is the Y-Z projection and the main image is 
the X-Y projection, all relative to the white lines identifying the XYZ positioning along the 3D z-
stack. 
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Bioconjugates do it better! Zeolite nanocrystals functionalized with tumor-targeting Cetuximab 
antibody undergo very fast cellular uptake by cancer cells, paving the way for the design of functional 
nanomaterials as potential theranostic platforms. 
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